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ABSTRACT
Objectives: Many economic evaluations are conducted in the ﬁelds of
oncology and hematology, partially owing to the introduction of new
expensive drugs in this ﬁeld. Even though inpatient days, outpatient visits,
and daycare treatments are frequently the main drivers of total treatment
costs, their unit costs often lack generalizability. Therefore, we aimed to
determine the unit costs of inpatient hospital days, outpatient visits, and
daycare treatments speciﬁcally for oncological and hematological diseases
in The Netherlands from the hospital’s perspective.
Methods: Unit costs were collected from 30 oncological and hematologi-
cal departments of 6 university and 24 general hospitals. Costs included
direct labor and indirect labor, hotel and nutrition, overheads and capital.
Ordinary least squares regression models were constructed to examine the
degree of association between unit costs and hospital and hospital depart-
ment characteristics. All costs were based on Euro 2007 cost data.
Results: At university hospitals, the unit costs per inpatient day were
determined at €633 in oncological and €680 in hematological depart-
ments. At general hospitals, the mean costs per inpatient day were €400.
Unit costs for inpatient hospital days, outpatient visits. and daycare treat-
ments equalled the relative ratio 100:21:44. Direct labor costs were the
major cost driver and the type of hospital (university, yes/no) was a strong
predictor of unit costs.
Conclusions: The present study provided unit costs for inpatient hospital
days, outpatient visits, and daycare treatments in the ﬁelds of oncology
and hematology. The results may be used as Dutch reference unit prices in
economic evaluations assessing oncological and hematological diseases.
Keywords: daycare treatment, hematology, inpatient hospital day, oncol-
ogy, outpatient visit, reference price, unit cost.
Introduction
The number and variety of treatment options for oncological and
hematological diseases have rapidly increased in the past
decades. The introduction of new expensive drugs in this ﬁeld has
caused hospital budgets in Western countries to be continuously
under pressure. Therefore, the need arose to assess these drugs in
terms of their costs and beneﬁts [1–5]. In The Netherlands,
pharmacoeconomic evidence is required after 3 years of initial
usage in daily practice to receive additional funding for expensive
inpatient drugs on top of the ﬁxed hospital budget [1,2]. Conse-
quently, many economic evaluations are conducted in the ﬁelds
of oncology and hematology.
Inpatient hospital days, outpatient visits, and daycare treat-
ments have proven to be important cost drivers in economic
evaluations determining the costs of alternative treatment
options in the management of oncological and hematological
diseases. Their unit costs should be accurate because they can
markedly affect the results of an economic evaluation [6,7].
Nevertheless, clear information disseminated to the public on the
unit costs of inpatient hospital days, outpatient visits, and
daycare treatments is lacking [7–9]. In the current practice of
economic evaluations, unit costs are usually calculated from the
speciﬁc health-care providers at which the economic evaluation is
performed (among others: [10–12]). These unit costs often lack
generalizability because health-care providers participating in
economic evaluations may not be representative of the overall
treatment patterns in a country [7–9]. To guarantee generaliz-
ability, the ideal unit prices are established from large, diverse
populations, which require data from multiple sources [13].
One earlier study has determined the unit costs of inpatient
hospital days in The Netherlands [7]. Oostenbrink et al. [7]
collected unit costs from 10 university and 12 general hospital
departments, of which 3 concerned the ear–nose–throat specialty,
7 concerned internal medicine, 1 concerned gynecology, 2 con-
cerned hematology, 4 concerned oncology, 2 concerned pulmo-
nary, and 3 concerned surgery. These unit costs were determined
to be €396 in university hospitals and €282 in general hospitals
(adjusted to 2007). The results of this study were used to develop
reference prices for inpatient hospital days in The Netherlands
and contribute to the comparability and generalizability of eco-
nomic evaluations [7,8].
Nevertheless, the reference prices developed by Oostenbrink
et al. [7] may not be sufﬁciently distinctive for use in the ﬁelds of
oncology and hematology because they are determined for use at
any medical specialty. Factors inﬂuencing the potential differ-
ences between the unit costs at any medical specialty and the unit
costs in the ﬁelds of oncology and hematology may include the
patient case-mix and medical practice patterns (e.g., number of
beds and the employment of an intensive care unit)
[7,9,10,14,15]. Therefore, the primary aim of the present study
was to determine the unit costs of inpatient hospital days, out-
patient visits, and daycare treatments speciﬁcally for oncological
and hematological diseases in The Netherlands from the hospi-
tal’s perspective.
The results of the obtained unit costs may give rise to the
question which factors are responsible for the differences in
costs between hospital departments. Therefore, the current study
additionally aimed to identify associations between collected
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descriptive hospital and hospital department characteristics and
the obtained unit costs.
Methods
Total costs of inpatient hospital days, outpatient visits, and
daycare treatments were determined separately for university and
general hospitals. For university hospitals, a further distinction
was made between oncology and hematology departments. For
general hospitals, no distinction was made between oncology and
hematology unit costs because oncology and hematology patients
are often admitted to general internal medicine departments.
Total cost estimates were determined by the identiﬁcation of
resource use and unit costs of the following cost components:
direct labor of medical specialists, residents, nurses and admin-
istrative staff; indirect labor of clinical and nonclinical depart-
ments (e.g., laundry and cleaning); hotel and nutrition; overheads
(general expenses, maintenance and energy, rent and leasing) and
capital (depreciation of inventory and interest). Costs of medical
imaging services, laboratory services and medications were
explicitly excluded from this study, because they are considered
to be highly dependent on the disease and treatment strategy
under consideration and often explain total cost differences
between alternative treatments in economic evaluations.
Unit costs were calculated using the microcosting methodol-
ogy, because this methodology provides cost estimations that
most accurately reﬂect actual costs by identifying all relevant cost
components at the most detailed level [6,16]. All costs were
based on Euro 2007 cost data. Where necessary, costs were
adjusted to 2007 using the general price index from the Dutch
Central Bureau of Statistics [17].
Recruitment of Hospitals
A sample of university and general hospitals was identiﬁed which
was representative of the overall practice setting and treatment
patterns in The Netherlands. For oncology, this concerned
departments which participated in the randomized phase III clini-
cal trial investigating sequential versus combination chemo-
therapy with capecitabine, irinotecan, and oxaliplatin in
advanced stage III/IV colorectal cancer carried out by the Dutch
Colorectal Cancer Group [18]. The hematological departments
were involved in the randomized phase III study on the effect of
thalidomide combined with adriamycin, dexamethasone, and
high-dose melphalan performed by the Dutch hemato-oncology
association (HOVON) in patients <65 years old with previously
untreated multiple myeloma (HOVON 50) [19].
Standardized Reporting Templates
At each of the qualiﬁed hospital departments, one medical spe-
cialist was asked personally by the investigators whether he/she
would like to participate in the study. Using standardized report-
ing templates, the participating medical specialists were asked to
provide resource use information retrospectively, based on best
estimations and separately for inpatient hospital days, outpatient
visits, and daycare treatments. Resource use information
included the direct labor minutes spent by medical specialists,
residents, nurses, and administrative staff attributable to an
average patient. Resource use of direct labor was valued with
standardized unit costs per minute, which equalled the normative
income (including social premiums, fees for irregular working
hours, and the costs of replacement during illness) divided by the
number of workable minutes per year. Normative incomes were
based on collective labor agreements. Because medical specialists
of general hospitals work in independent corporations and are
not on the payroll of the hospital, the normative income for these
medical specialists are based on a national rate that also includes
overhead costs. Subsequently, their unit costs are substantially
higher than those for medical specialists of university hospitals
(€2.50 vs. €1.46 per minute). Therefore, the normative income of
university hospitals (€1.46 per minute) was used to value medical
specialists’ time at both university and general hospitals.
Annual Accounts
The annual accounts of the year 2006 of the hospital depart-
ments were acquired to obtain input data for the cost calculation
of indirect labor, hotel and nutrition, overheads and capital.
Annual costs of hotel and nutrition were divided by the annual
number of inpatient hospital days to be able to appoint hotel and
nutrition use to inpatient hospital days. Annual costs of indirect
labor, overheads and capital were divided by the annual costs of
patient-related care. Subsequently, this “mark-up percentage”
was multiplied by the summed daily costs of direct labor and
hotel and nutrition.
Sensitivity Analyses
To determine the uncertainty of the obtained cost estimates for
university as well as general hospitals, one-way sensitivity analy-
ses were carried out by varying the resource use and unit cost
values of the individual cost components between 50% and
150%. Furthermore, at six (random) general hospital depart-
ments, one nurse was additionally asked to provide resource use
data on daycare treatments to verify the information obtained
from medical specialists.
Statistical Analyses
In addition to descriptive statistics, one-way analyses of variance
with and without post hoc testing (type Bonferroni) were used to
investigate cost differences between hospitals. Besides, all hospi-
tal departments were included in an ordinary least squares (OLS)
regression analysis to explore the degree of association between
total costs (dependent variable) and collected hospital and hos-
pital department characteristics (explanatory variables). Hospital
characteristics included “type of hospital” (university, yes/no),
“number of beds at the hospital” and “number of inpatient days
per year.” Department characteristics involved “number of
medical specialists” in combination with “number of beds at the
department” and “number of patients per day” for inpatient
hospital days, “number of visits per day” and “mean duration of
a visit” for outpatient visits, and “number of beds at the daycare
treatment” and “number of patients per day” for daycare treat-
ments. Statistical analyses were conducted with the statistical
software programmes SPSS for Windows version 15.0 (SPSS Inc.,
Chicago, IL).
Results
For university hospitals, the medical specialists of 3 oncology
departments (UH1-3) and 3 hematology departments (UH3-5)
were willing to cooperate. For general hospitals, a total of 24
departments (GH1-24) agreed to contribute. During the course
of the data collection, one department (GH-24) was unable to
provide detailed resource use information on inpatient hospital
days. Furthermore, three departments (GH-9, GH-13, GH-24)
were unable to provide detailed resource use information on
outpatient visits and three departments (GH-7, GH-14, GH-22)
on daycare treatments. Therefore, these departments were
excluded from further analyses.
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Inpatient Hospital Days
Table 1 presents the cost distribution for inpatient hospital days
per oncology and hematology department at university hospitals.
Unit costs at hematology departments varied between €630 and
€734 (n = 3) and those at oncology departments between €540
and €704 (n = 3; P = 0.469). Both the number of beds and the
number of patients per inpatient day were slightly, but not sig-
niﬁcantly, higher at oncology departments. No signiﬁcant cost
differences of individual cost components were found between
the oncology and hematology departments.
Table 2 shows the cost distribution for inpatient hospital days
at general hospitals. Unit costs at general hospitals amounted to
€400 (range: from €296 to €556; n = 23) and were about 39%
lower than those at university hospitals (P < 0.001). In all hos-
pitals, direct labor costs were the major cost component and
ranged from 45% to 59%. Nurses were the greatest attributors
to the direct labor costs (between 25% and 67% of direct labor
costs).
Outpatient Visits
Table 3 presents the unit costs of outpatient visits at university
hospitals separately for oncology and hematology. Total costs per
outpatient visit ranged from €99 to €132 at oncology depart-
ments (n = 3) and from €125 to €158 at hematology departments
(n = 3; P = 0.212). The number of outpatient visits per day per
medical specialist was slightly, but not signiﬁcantly, higher at
oncology departments.
Table 4 summarizes the unit costs of outpatient visits at
general hospitals. Unit costs at general hospitals were €86 (range:
from €45 to €193; n = 21) and were about 34% lower than those
at university hospitals (P = 0.008). At all hospitals, direct labor
costs were the most important cost driver, with medical special-
ists as the greatest contributor (between 50% and 89% of direct
labor costs).
Daycare Treatments
Table 3 also presents the unit costs of daycare treatments at
university hospitals separately for oncology and hematology.
Unit costs at hematology departments were €305 (range: from
€276 to €328; n = 3) and approximately 11% higher than those
at oncology departments (€276; range: from €250 to €314; n = 3;
P = 0.310). The number of beds at the daycare treatment was
slightly, but not signiﬁcantly, higher at oncology departments.
Table 4 summarizes the unit costs of daycare treatments at
general hospitals. Unit costs at general hospitals amounted to
€176 (range: from €96 to €382; n = 21) and were about 39%
lower than those at university hospitals (P = 0.001). At all hos-
pitals, direct and indirect labor costs accounted for about 50%
and 18% of the total costs. Nurses were the greatest attributors
to the direct labor costs (50% of direct labor costs). The share of
medical specialist costs was higher at university (34% of direct
labor costs) than at general hospitals (21% of direct labor costs;
P = 0.001).
Sensitivity Analyses
For all unit costs, the greatest variation in the total costs was
found when direct labor minutes of either medical specialists or
nurses was altered, but the deviation was limited to 4–23%.
For the cost calculation of hotel and nutrition, changing the
number of inpatient hospital days per year resulted in a variation
in the total costs of 5–8%. For the cost calculation of indirect
labor, overheads or capital, total costs deviated to only 3–11%
when the respective mark-up percentages were altered.
At six general hospital departments, one nurse was addition-
ally asked to provide resource use data on daycare treatments to
verify the information obtained from medical specialists. No
signiﬁcant differences were found between the resource use
acquired from medical specialists and nurses (P = 0.530).
OLS Regression
Table 5 shows the models of the OLS regression that were con-
structed to examine the degree of association between total costs
and hospital and hospital department characteristics. For inpa-
tient hospital days, model 1a included all associated characteris-
tics, of which only “type of hospital” (P = 0.002) and “number
of patients per day” (P = 0.107) were associated with total costs.
When the nonsigniﬁcant variables were left out (model 1b), using
a cutoff value of P > 0.200, “number of patients per day” lost its
signiﬁcance. Model 1c included “type of hospital” only and was
able to explain 72% of total costs. The university hospital type
was associated with an increase in costs of €256 (P < 0.001).
For outpatient visits, model 2a included all associated char-
acteristics, of which only “type of hospital” (P = 0.037) and
Table 1 Inpatient hospital day: cost distribution per university hospital
Hospital ID
Oncology Hematology
UH-1 UH-2 UH-3 Mean
Standard
deviation UH-3 UH-4 UH-5 Mean
Standard
deviation
Number of beds at the hospital (n) 953 882 1221 1019 179 1221 1042 733 999 247
Annual number of inpatient days at the hospital (n ¥ 1000) 213 138 306 219 84 306 238 164 236 71
Number of medical specialists at the department (n) 12 8 21 14 7 13 9 6 9 3
Number of beds at the inpatient department (n) 20 16 42 26 14 16 16 19 17 2
Number of patients per day at the inpatient department (n) 18 16 32 22 9 16 15 19 17 2
Direct labor (€) 281 293 370 314 48 351 343 295 330 30
Medical specialists 83 79 169 110 51 136 90 110 112 23
Residents 58 65 65 63 4 65 59 46 57 10
Nurses 126* 132 123 128 6 142 178 125 148 27
Administrative staff 14 16 12 14 2 8 17 13 13 4
Indirect labor (€) 101 163 134 133 31 128 141 123 131 9
Hotel and nutrition (€) 64 74 85 74 11 85 111 98 98 13
Overheads (€) 59 87 80 76 14 77 90 79 82 7
Capital (€) 34 40 35 36 3 34 49 35 39 8
Total costs (€) 540 656 704 633 85 675 734 630 680 52
*Missing value.
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“mean duration of a visit” (P < 0.001) were associated with total
costs. When only these variables were included in the OLS regres-
sion (model 2b), the university hospital type was associated with
a cost increase of €46 (P = 0.001) and one additional minute of
duration of a visit with a cost increase of €4 (P = 0.001). Model
2b was able to explain only 54% of total costs.
For daycare treatments, model 3a included all associated
characteristics, of which only “number of beds at the hospital”
(P = 0.621) and “number of medical specialists” (P = 0.429)
were not associated with total costs. When these nonsigniﬁcant
variables were left out (model 3b), using a cutoff value of
P > 0.200, the regression analysis showed cost increases for
“type of hospital,” “number of inpatient days” and “number of
beds at the daycare treatment,” and a cost decrease for “number
of patients per day”. The latter analysis explained 64% of total
costs.
Conclusions
Including a total of 30 hospital departments, this study is the
most extensive cost assessment of unit costs for inpatient hospital
days, outpatient visits, and daycare treatments in the ﬁelds of
oncology and hematology in The Netherlands thus far. With
respect to inpatient hospital days at university hospitals, total
costs were €633  85 for oncology and €680  52 for hematol-
ogy. Unit costs at hematology departments were approximately
7% higher than those at oncology departments (P = 0.469). For
general hospitals, no distinction was made between oncology and
hematology unit costs because oncology and hematology patients
are often admitted to general internal medicine departments.
Total costs at general hospitals were €400  67, with direct labor
costs contributing to about half of the total costs.
Oostenbrink et al. determined the unit costs of inpatient hos-
pital days at any medical specialty. Even though they additionally
included medication and blood products, Oostenbrink et al.
found the unit costs of inpatient hospital days to be substantially
lower than those found in our study. Total costs in their sub-
sample of hematology (n = 2) and oncology departments (n = 4)
amounted to €327 and €303, respectively (adjusted to 2007) [7].
The methodology used to derive the direct labor cost estimates of
residents and nurses may partly explain this difference. Although
medical specialists were asked to estimate the direct labor
minutes spent per inpatient hospital day in our study, Oosten-
brink et al. divided the annual costs of residents and nurses by
the annual number of inpatient hospital days. The higher cost
estimations in our study directly inﬂuenced overhead and capital
costs, because these were determined using a marginal mark-up
percentage. Nevertheless, in agreement with our results, Oosten-
brink et al. found total hematology costs to be 8% more expen-
sive than total oncology costs and observed direct labor costs to
contribute to about 51% of total costs.
Our results further suggest that total costs for inpatient hos-
pital days, outpatient visits, and daycare treatments equalled the
relative ratio 100:21:44 (Tables 3 and 4), which is fairly in line
with the results of other studies. Oostenbrink et al. found the
relative ratio in general hospitals to be 100:17:46 (€282, €49,
€128; adjusted to 2007) [8]. Van Agthoven et al., who performed
an economic evaluation in patients with stage II/III multiple
myeloma at the hematology departments of 2 university and 6
general hospitals, observed a relative ratio of 100:25:45 (€463, €
109, €207; adjusted to 2007) [20]. Ward et al., who compared
the cost-effectiveness of different treatment options in patients
with metastatic colorectal cancer in the United Kingdom, used
unit costs with a relative ratio of 100:20:30 (€632, €131, €191;
adjusted to 2007) [21].Ta
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Our OLS regression may give some indications on the factors
responsible for the differences in costs between hospital depart-
ments. It was concluded that the “type of hospital” (university,
yes/no) was able to predict up to 72% of the total costs for
inpatient hospital days. The “type of hospital” was also a strong
predictor with respect to outpatient visits, in combination with
“mean duration of a visit,” and regarding daycare treatments,
combined with “number of inpatient days,” “number of beds at
the daycare treatment,” and “number of patients per day”. Oos-
tenbrink et al. have also performed regression analyses but none
of their independent variables showed a relationship with total
costs that came near to signiﬁcance.
The cost calculations on oncology and hematology each were
based on data of the hospital departments of 3 of 8 university
hospitals in The Netherlands. There are indications that the
included departments may be accurate representatives to Dutch
university hospitals. In 2006, 36% and 39% of inpatient hospital
days at university hospitals were attributable to the oncology and
hematology departments of our university hospitals, respectively.
The average number of beds per university hospital in our sample
was 966 beds, which is close to the average number of beds per
university hospital in The Netherlands (997 beds) [17]. Besides,
the university hospitals in our study were located at different
regions of the country.
Although we faced some missing data during the course of
the data analyses, the extent to which data were missing was
limited. Because hospitals in The Netherlands are obliged to
give details on a predetermined list of cost components by
means of their publicly available annual accounts, no data
were missing on indirect labor, hotel and nutrition, overheads
and capital. Regarding direct labor minutes, six hospitals
(GH-7, GH-9, GH-13, GH-14, GH-22, and GH-24) were
unable to provide detailed resource use information on inpa-
tient hospital days and/or outpatient visits and/or daycare treat-
ments and were therefore excluded from the individual
analyses. Of the remaining oncology departments, only 7.8%
of the required items in university hospitals and 5.6% of those
in general hospitals were missing. Sensitivity analyses have also
demonstrated that our study resulted in fairly robust cost
estimates.
The microcosting methodology is ideally combined with the
bottom-up approach, in which cost components are valued by
identifying resource use directly employed for a patient [16,22].
Nevertheless, our study applied the top-down approach in which
cost components are valued by separating out the relevant costs
from comprehensive sources (e.g., annual accounts). Addition-
ally, lack of detailed data prevented us from assessing the costs of
overheads and capital by means of more conventional methods,
such as cost center allocation or inpatient day allocation [8,23].
Alternatively, marginal mark-up allocation was used for the cost
estimation of overheads and capital. Previous studies concluded
that the top-down approach may be a good proxy to the
bottom-up approach and that marginal mark-up allocation may
be sufﬁciently accurate for hospital services which are not
expected to vary widely between patients [8,16,22,23]. This was
the case in the present study, as the costs of medical imaging
services, laboratory services, and medications were explicitly
excluded. Costs of medical imaging services, laboratory services,
and medications are considered to be highly dependent on the
disease and treatment strategy and often explain total cost dif-
ferences between alternative treatments. Therefore, we believe
that the use of a top-down approach and marginal mark-up
allocation did not markedly affect the results of the present study.
Inpatient hospital days, outpatient visits, and daycare treat-
ments form important cost drivers in economic evaluations,
but information on their unit costs is often lacking [7–9].
The present study provided unit costs for inpatient hospital
days, outpatient visits, and daycare treatments in the ﬁelds of
oncology and hematology. The results may be used as reference
unit prices in economic evaluations assessing new expensive
drugs for oncological and hamatological diseases in The
Netherlands.
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Table 4 Unit cost of inpatient hospital day, outpatient visit, and daycare treatment at general hospitals
Inpatient day Outpatient visit Daycare treatment
(n = 23) (n = 21) (n = 21)
Mean
Standard
deviation Mean
Standard
deviation Mean
Standard
deviation
Number of beds at the hospital (n) 563 231 577 231 623 284
Annual number of inpatient days at the hospital (n ¥ 1000) 125 62 127 62 137 70
Number of medical specialists at the department (n) 3 2 3 2 3 2
Number of beds at the inpatient department (n) 22 7
Number of patients per day at the inpatient department (n) 20 6
Number of outpatient visits per day per medical specialist (n) 21 6
Average duration of an outpatient visit (minutes) 15 6
Number of beds at the daycare treatment (n) 13 8
Number of patients per day at the daycare treatment (n) 19 8
Direct labor (€) 212 38 54 24 91 38
Medical specialists 60 42 38 20 19 16
Residents 40 20 0 0 5 7
Nurses 103 26 10 6 49 23
Administrative staff 8 3 5 3 18 11
Indirect labor (€) 70 17 15 6 30 14
Hotel and nutrition (€) 37 9 0 0 18 5
Overheads (€) 41 10 9 4 18 8
Capital (€) 41 14 9 5 19 9
Total costs (€) 400 67 86 36 176 68
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